The establishment of Vnzymes in Frankfurt represents a strategic step in VTR Biotech’s international growth. The European office will focus on accelerating innovation in animal nutrition and health, ...
In 2025, Sapphire RX was honored with an Outstanding Achievement Award in Modern Wellness Care, recognizing its commitment to advancing secure and compassionate telehealth services. This ...
The Company will use the proceeds of the First Tranche of the Offering towards advancing its Alzheimer’s Disease (“ AD ”) program including the opening of its first U.S. AD clinic, general and ...
In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 150,000 shares at the public offering price, less the underwriting discounts and commissions.
Cleveland, Ohio, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public impact investing company dedicated to acquiring, reclaiming and ...
COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) (“COSCIENS” or the “Company”), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that Peter H.
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results
IRVINE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its third quarter 2025 operating and financial results and reviewed recent ...
Goldman Sachs & Co. LLC, TD Cowen and Wells Fargo Securities acted as joint book-running managers for the offering.
CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to ...
TORONTO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and ...
Gross margin was 81.9% for the three months ended June 30, 2025, as compared to 75.3% in the corresponding prior year quarter. This reflects the expansion of our recurring technology fee revenue base, ...
A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com. A replay of the webcast will be archived on Terns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback